Literature DB >> 29262402

Sacubitril/Valsartan in "Field Practice" Patients with Advanced Heart Failure: A Monocentric Italian Experience.

Antonella Vincenzi1, Francesca Cesana, Antonio Cirò, Laura Garatti, Felice Achilli.   

Abstract

Patients with advanced heart failure (HF) experience a continuous decline in quality of life and have a very poor prognosis. Moreover, due to numerous comorbidities present in these patients, transplantation and left ventricular assist devices are usually impracticable in clinical practice. In this challenging setting, administration of inotropic agents may be the only possible therapy; however, this treatment requires frequent hospitalizations. Our hypothesis is that sacubitril/valsartan, given its marked efficacy and manageability, can be safely used in clinical practice in this setting, potentially reducing hospitalizations and the need for inotropic support. We report here our experience in a small series of patients with advanced HF treated with sacubitril/valsartan.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Angiotensin receptor-neprilysin inhibitor; Heart failure; Sacubitril; Valsartan

Mesh:

Substances:

Year:  2017        PMID: 29262402     DOI: 10.1159/000484877

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  1 in total

1.  Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry.

Authors:  Michele Correale; Adriana Mallardi; Pietro Mazzeo; Lucia Tricarico; Claudia Diella; Valentina Romano; Armando Ferraretti; Alessandra Leopizzi; Giuseppina Merolla; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Int J Cardiol Heart Vasc       Date:  2020-02-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.